A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients

Abstract

Multiple myeloma (MM) is a heterogeneous group of disorders both genotypically and phenotypically. Response to thalidomide-based induction therapy in newly diagnosed patients varies significantly in published clinical trials. Proteomic analysis was performed on 39 newly diagnosed MM patients treated with a thalidomide-based regimen (22 responders; 17 non-responders) using immunodepletion, 2-D DIGE analysis and mass spectrometry. Zinc-a-2-glycoprotein (ZAG), vitamin D-binding protein (VDB), serum amyloid-A protein (SAA) and b-2-microglobulin (B2M) had statistically significant higher concentrations in non-responders compared to responders, while haptoglobin (Hp) had a lower concentration. ELISAs were used to validate the candidate protein biomarkers using unfractionated serum from 51 newly diagnosed MM patients (29 responders; 22 non-responders). Using logistic regression, the best possible area under the curve (AUC) was 0.96 using ZAG, VDB and SAA in combination. Leave-one-out-cross-validation (LOOCV) indicated an overall predictive accuracy of 84% with associated sensitivity and specificity values of 81.8 and 86.2%, respectively. Subsequently, 16 of 22 thalidomide-refractory patients successfully achieved complete response or very good partial response using second-line treatment suggesting that the biomarker profile is specific to thalidomide response rather than identifying patients with MM refractory to all therapies. Using a novel panel of predictive biomarkers, the feasibility of predicting response to thalidomide-based therapy in previously untreated MM has been demonstrated.

Evaluation of inflammatory biomarkers as helping diagnostic tool in patients with breast cancer

“…Numerous studies indicate that a combined approach with simultaneous measurement of multiple biomarkers may improve the diagnostic value of any single serum biomarker [46][47][48][49]. However, even large scale, high trough output, studies reached unsatisfactory levels of sensitivity or specificity [50][51][52][53].…”

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

“…However, GEP is not only finding application in the molecular classification of patients but is also being investigated as a method to identify factors associated with toxicities seen with certain treatments [118 -122], which may in the future enable the identification of patients likely to succumb to particular adverse events and may therefore provide a way of personalizing treatment. Moreover, molecular techniques may find application in guiding treatment decisions by predicting response to treatment [123].…”

Mass Spectrometry-Based Identification of Muscle-Associated and Muscle-Derived Proteomic Biomarkers of Dystrophinopathies

“…Removal of high-abundance proteins and consequently the establishment of an enriched pool of low-abundance proteins enable improved resolution and a compressed dynamic range for biomarker discovery experiments using label-free shotgun profiling with LC-MS/MS analysis, as well as two-dimensional gel-based techniques. Immuno-depletion of clinical samples has facilitated the discovery of many candidate biomarkers and is now routinely used as a robust strategy to help overcome some of the problems associated with dynamic range [87,88]. However, immunodepletion is not without some drawbacks.…”